BMGF – Gates Foundation  [to 5 Jan 2019]
No new digest content identified.
Bill & Melinda Gates Medical Research Institute    [to 5 Jan 2019]
The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world’s poorest people
No new digest content identified.
CARB-X   [to 5 Jan 2019]
CARB-X is a non-profit public-private partnership dedicated to accelerating antibacterial research to tackle the global rising threat of drug-resistant bacteria.
01.03.2019  |
CARB-X backs Forge to develop a new class of antibiotics to treat serious lung infections caused by Gram-negative bacteria, including multi-drug resistant P. aeruginosa
CARB-X is awarding Forge Therapeutics of San Diego, CA, USA, up to $5.7 million in non-dilutive funding, with the possibility of up to $5.4 million more if certain project milestones are met, to develop a novel antibiotic to treat serious lung infections caused by Gram-negative bacteria including multi-drug resistant Pseudomonas aeruginosa. This is Forge’s second project to earn CARB-X support..
CEPI – Coalition for Epidemic Preparedness Innovations  [to 5 Jan 2019]
No new digest content identified.
EDCTP    [to 5 Jan 2019]
The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials
Latest news
No new digest content identified.
Emory Vaccine Center    [to 5 Jan 2019]
No new digest content identified.
European Medicines Agency  [to 5 Jan 2019]
News and press releases
News: Human medicines: highlights of 2018
European Vaccine Initiative  [to 5 Jan 2019]
27 December 2018
TRANSVAC2 success story published by EC
European Commission highlights that EU-funded TRANSVAC2 project is developing infrastructure to support innovation and…
FDA [to 5 Jan 2019]
No new digest content identified.
Fondation Merieux  [to 5 Jan 2019]
Mérieux Foundation co-organized event
Dengue pre-vaccination screening based on serostatus: rapid tests and implementation strategies
January 14 – 16, 2019 – Les Pensières Center for Global Helath, Veyrier du Lac (France)
Gavi [to 5 Jan 2019]
No new digest content identified.
GHIT Fund   [to 5 Jan 2019]
GHIT was set up in 2012 with the aim of developing new tools to tackle infectious diseases that devastate the world’s poorest people. Other funders include six Japanese pharmaceutical
No new digest content identified.
Global Fund  [to 5 Jan 2019]
No new digest content identified.
Hilleman Laboratories   [to 5 Jan 2019]
No new digest content identified.
Human Vaccines Project   [to 5 Jan 2019]
No new digest content identified.
IAVI  [to 5 Jan 2019]
No new digest content identified.
No new digest content identified.
IVAC  [to 5 Jan 2019]
No new digest content identified.
IVI   [to 5 Jan 2019]
IVI News & Announcements
No new digest content identified.
JEE Alliance  [to 5 Jan 2019]
No new digest content identified.
MSF/Médecins Sans Frontières  [to 5 Jan 2019]
Selected News; Project Updates, Reports
Access to medicines
Calling on governments to scale up oral TB treatment
Press Release 22 Dec 2018
Geneva — Médecins Sans Frontières (MSF) today welcomed new World Health Organization (WHO) treatment guidelines that recommend drug-resistant tuberculosis (DR-TB) be treated with oral drugs only, including newer, more potent drugs with fewer side effects, such as bedaquiline.
Two injectable drugs known to cause deafness and other severe side effects are no longer recommended in the new guideline – an important step towards more tolerable treatment for all patients.
The recommended 18 to 20-month treatment regimen includes more potent drugs – bedaquiline, linezolid, levofloxacin and moxifloxacin – that can help improve cure rates, reduce deaths and cause people far fewer side effects.
MSF called on countries with large numbers of people with DR-TB to urgently start implementing these new treatment guidelines for at least half of new DR-TB cases by September 2019, and to make efforts to reach all people in need by March 2020…
NIH  [to 5 Jan 2019]
January 2, 2019
NIH study implicates hyperactive immune system in aging brain disorders
— Results suggest a breakdown in brain cell waste system triggers a destructive immune reaction.
PATH  [to 5 Jan 2019]
January 1, 2019 by PATH
Community-based HIV testing effective in reaching undiagnosed populations, PATH-led study finds
Lay provider HIV testing in Vietnam offers new model to connect at-risk populations with antiretroviral therapy
Hanoi, Vietnam, January 1, 2019—One in three people living with HIV in Vietnam remain undiagnosed, according to recent estimates. New strategies and models of HIV testing are urgently needed to reach undiagnosed populations and help them enroll in antiretroviral therapy (ART), in Vietnam and throughout the world.
Results from an evaluation study now published in PLOS ONE demonstrate that HIV testing by lay providers can serve as a critical addition to efforts to achieve the United Nations’ 90-90-90 global HIV targets by 2020 and help to cover the “last mile” of HIV services to at-risk populations in Vietnam…
Sabin Vaccine Institute  [to 5 Jan 2019]
No new digest content identified.
UNAIDS [to 5 Jan 2019]
Selected Press Releases/Reports/Statements
27 December 2018
First Lady of Botswana champions revitalization of HIV prevention among adolescent girls and young women
UNICEF  [to 5 Jan 2019]
Selected Press Releases/Reports/Statements
Press release
Lives of children at risk amid heavy fighting and floods in north-west Syria
Nearly 10,000 children fleeing floods in the area
Press release
New Year’s Babies: Over 395,000 children will be born worldwide on New Year’s Day – UNICEF
As the calendar turns to 2019, UNICEF calls on nations to meet every newborn’s right to health and survival
Press release
World has failed to protect children in conflict in 2018: UNICEF
Widespread violations against children in conflict continue in shocking year-on-year trend
[See Milestones above for detail]
Vaccine Confidence Project  [to 5 Jan 2019]
Confidence Commentary:
Reflections for the New Year: Thank you Dr. Frankenstein
Heidi Larson | 28 Dec, 2018
2018 has been a year of anniversaries – particularly the devastating “Spanish” influenza pandemic, which peaked in 1918, and the armistice ending the First World War. But it also marked 200 years since the 1818 publication of Mary Shelley’s “Frankenstein; or, The Modern Prometheus”. This is a riveting tale of hubris, of fascination to know more and more, and of man playing God, creating a monster and then abandoning him, leaving to find his own way.

Having neglected his creation, and faced with unanticipated revenge by his own invention, Frankenstein bemoans his regret at ignoring “the duties of a creator towards his creature”.

Shelley’s novel was one of the earliest, if not the first, science fiction novel, with insights into the human condition, and man’s struggle with desire to know more and more, yet unprepared to deal with the consequence. She was writing at the dawn of a new era of electricity, of power, of science and possibility – an era not unlike our own.

Frankenstein offers us a lesson in anticipating the implications of our scientific discovery and innovation, of being too focused on technology and its inherent power, of being perhaps obsessed with the notion of “disruption” as progress, while giving little consideration to its accidentally negative, or even malevolent, consequences.

The bicentenary of Frankenstein struck me as an apt anniversary to reflect and conclude the year on, as we are increasingly confronted with the risks and consequences of social media and global connectivity. The algorithms that live behind the screen, as well as human intentions behind them, are manipulating and polarizing public emotions, fears and perceived truths.

Anonymous or constructed identities are misleading individuals, with bots and trolls embedding the vaccine debates, not just to undermine vaccines, but as a platform – a Trojan Horse – to further destabilize democracy and foster discontent.  In other instances, the spotlight has been on companies – driven by growth – using and abusing personal data generated through social media, for furthering their own profits.

It is no wonder public trust is waning…
Vaccine Education Center – Children’s Hospital of Philadelphia  [to 5 Jan 2019]
No new digest content identified.
Wellcome Trust  [to 5 Jan 2019]
News | 29 December 2018
Wellcome leaders awarded New Year Honours
Jeremy Farrar, Wellcome’s Director, and Mike Ferguson, Deputy Chair of our Board of Governors, have both been knighted in the New Year’s Honours 2019.
The Wistar Institute   [to 5 Jan 2019]
No new digest content identified.
World Organisation for Animal Health (OIE)   [to 5 Jan 2019]
No new digest content identified.
BIO    [to 5 Jan 2019]
No new digest content identified.
DCVMN – Developing Country Vaccine Manufacturers Network  [to 5 Jan 2019]
20 December 2018
Bill Gates: “looking forward to the partnerships we can have over the next decade”
Kunming, 30th October 2018 – Vaccine manufacturers from emerging countries convened in Kunming, China, to consider vaccine industry partnerships to help advance global health initiative. A.Oswald interviewed Bill Gates (by recorded video), reflecting on achievements of the first decade of vaccines…
bill_gates_kunming_video_news.pdf (PDF – 203.3 kb)
IFPMA   [to 5 Jan 2019]
No new digest content identified.
PhRMA    [to 5 Jan 2019]
No new digest content identified.
Industry Watch    [to 5 Jan 2019]
:: FDA Approves VAXELIS, Sanofi and MSD’s Pediatric Hexavalent Combination Vaccine
PARIS and KENILWORTH, N.J. – December 26, 2018 – The U.S. Food and Drug Administration has approved VAXELIS™ (Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed, Inactivated Poliovirus, Haemophilus b Conjugate [Meningococcal Protein Conjugate] and Hepatitis B [Recombinant] Vaccine) for use in children from 6 weeks through 4 years of age (prior to the 5th birthday). VAXELIS was developed as part of a joint-partnership between Sanofi and MSD (NYSE: MRK), known as Merck inside the United States and Canada.
Sanofi and MSD are working to maximize production of VAXELIS to allow for a sustainable supply to meet anticipated U.S. demand. Commercial supply will not be available in the U.S. prior to 2020…